Cross-cultural and construct validity of the Animated Activity Questionnaire

International audienc

Utilization of Partially Gasified Coal for Mercury Removal

In this project, General Electric Energy and Environmental Research Corporation (EER) developed a novel mercury (Hg) control technology in which the sorbent for gas-phase Hg removal is produced from coal in a gasification process in-situ at a coal burning plant. The main objective of this project was to obtain technical information necessary for moving the technology from pilot-scale testing to a full-scale demonstration. A pilot-scale gasifier was used to generate sorbents from both bituminous and subbituminous coals. Once the conditions for optimizing sorbent surface area were identified, sorbents with the highest surface area were tested in a pilot-scale combustion tunnel for their effectiveness in removing Hg from coal-based flue gas. It was determined that the highest surface area sorbents generated from the gasifier process ({approx}600 m{sup 2}/g) had about 70%-85% of the reactivity of activated carbon at the same injection rate (lb/ACF), but were effective in removing 70% mercury at injection rates about 50% higher than that of commercially available activated carbon. In addition, mercury removal rates of up to 95% were demonstrated at higher sorbent injection rates. Overall, the results of the pilot-scale tests achieved the program goals, which were to achieve at least 70% Hg removal from baseline emissions levels at 25% or less of the cost of activated carbon injection

Spinal cord magnetic resonance imaging in autosomal dominant hereditary spastic paraplegia

Hereditary spastic paraplegia (HSP) is a genetically heterogeneous group of neurodegenerative disorders characterized by progressive lower extremity weakness and spasticity. HSP pathology involves axonal degeneration that is most pronounced in the terminal segments of the longest descending (pyramidal) and ascending (dorsal columns) tracts. In this study, we compared spinal cord magnetic resonance imaging (MRI) in 13 HSP patients with four different types of autosomal dominant hereditary spastic paraplegia (SPG3A, SPG4, SPG6, and SPG8) with age-matched control subjects. The cross-section area of HSP subjects at cervical level C2 was 59.42±12.57 mm 2 and at thoracic level T9 was 28.58±5.25 mm 2 . Both of these values were less than in the healthy controls ( p <0.001). The degree of cord atrophy was more prominent in patients with SPG6 and SPG8 who had signs of severe cord atrophy (47.60±6.58 mm 2 at C2, 21.40±2.4 mm 2 at T9) than in subjects with SPG3 and SPG4 (66.0±8.94 mm 2 at C2, p <0.02; 31.75±2.76 mm 2 at T9, p <0.001). These observations indicate that spinal cord atrophy is a common finding in the four genetic types of HSP. Spinal cord atrophy was more severe in SPG6 and SPG8 HSP subjects than in other types of HSP we studied. This may suggest a different disease mechanism with more prominent axonal degeneration in these two types of HSP when compared with HSP due to spastin and atlastin mutations.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/46666/1/234_2005_Article_1415.pd

Restitution of superoxide generation in autosomal cytochrome-negative chronic granulomatous disease (A22(0) CGD)-derived B lymphocyte cell lines by transfection with p22phax cDNA

The respiratory burst oxidase of phagocytes and B lymphocytes is a multicomponent enzyme that catalyzes the one-electron reduction of oxygen by NADPH. It is responsible for the O2-production that occurs when these cells are exposed to phorbol 12-myristate 13-acetate or physiologic stimuli, such as phagocytosis in phagocytes or cross- linking of surface immunoglobulin in B lymphocytes. The activity of this enzyme is greatly diminished or absent in patients with chronic granulomatous disease (CGD), an inherited disorder characterized by a severe defect in host defense against bacteria and fungi. In every CGD patient studied so far, an abnormality has been found in a gene encoding one of the four components of the respiratory burst oxidase: the membrane proteins p22phox or gp91phox which together form the cytochrome b558 protein, or the cytosolic proteins p47phox or p67phox. Autosomal recessive cytochrome-negative CGD (A22(0) CGD) is associated with mutations in the gene coding for p22phox. We report here that the capacity for O2- production and cytochrome b558 protein expression were restored to Epstein-Barr virus-transformed B lymphocytes from two A22(0) CGD patients by transfection with an expression plasmid containing a p22phox cDNA. No detectable O2- was generated by untransfected p22phox-deficient lymphocytes. The genetic reconstitution of the respiratory burst in A22(0) CGD B lymphocytes by transfer of the wild-type p22phox cDNA represents a further step towards somatic gene therapy for this subgroup of A22(0) CGD. This system will also be useful for expression of genetically engineered mutant p22phox proteins in intact cells, facilitating the structure-function analysis of cytochrome b558

Second Generation Advanced Reburning for High Efficiency NOx Control

This project develops a family of novel Second Generation Advanced Reburning (SGAR) NO{sub x} control technologies, which can achieve 95% NO{sub x} control in coal fired boilers at a significantly lower cost than Selective Catalytic Reduction (SCR). The conventional Advanced Reburning (AR) process integrates basic reburning and N-agent injection. The SGAR systems include six AR variants: (1) AR-Lean--injection of the N-agent and promoter along with overfire air; (2) AR-Rich--injection of N-agent and promoter into the reburning zone; (3) Multiple Injection Advanced Reburning (MIAR)--injection of N-agents and promoters both into the reburning zone and with overfire air; (4) AR-Lean + Promoted SNCR--injection of N-agents and promoters with overfire air and into the temperature zone at which Selective Non-Catalytic Reduction (SNCR) is effective; (5) AR-Rich + Promoted SNCR--injection of N-agents and promoters into the reburning zone and into the SNCR zone; and (6) Promoted Reburning + Promoted SNCR--basic or promoted reburning followed by basic or promoted SNCR process. The project was conducted in two phases over a five-year period. The work included a combination of analytical and experimental studies to confirm the process mechanisms, identify optimum process configurations, and develop a design methodology for full-scale applications. Phase I was conducted from October, 1995 to September, 1997 and included both analytical studies and tests in bench and pilot-scale test rigs. Phase I moved AR technology to Maturity Level III-Major Subsystems. Phase II is conducted over a 45 month period (October, 1997-June, 2001). Phase II included evaluation of alternative promoters, development of alternative reburning fuel and N-Agent jet mixing systems, and scale up. The goal of Phase II was to move the technology to Maturity Level I-Subscale Integrated System. Tests in combustion facility ranging in firing rate from 0.1 x 10{sup 6} to 10 x 10{sup 6} Btu/hr demonstrated the viability of the AR technology. The performance goals of the project to reduce NO{sub x} by up to 95% with net emissions less than 0.06 lb/10{sup 6} Btu and to minimize other pollutants (N{sub 2}O and NH{sub 3}) to levels lower than reburning and SNCR have been met. Experimental data demonstrated that AR-Lean + SNCR and Reburning + SNCR are the most effective AR configurations, followed by AR-Lean and AR-Rich. Promoters can increase AR NO{sub x} reduction efficiency. Promoters are the most effective at small amounts of the reburning fuel (6-10% of the total fuel heat input). Promoters provide the means to improve NO{sub x} reduction and simultaneously decrease the amount of reburning fuel. Tests also showed that alkali-containing compounds are effective promoters of the AR process. When co-injected with N-agent, they provide up to 25 % improvement in NO{sub x} reduction. A detailed reaction mechanism and simplified representation of mixing were used in modeling of AR processes. Modeling results demonstrated that the model correctly described a wide range of experimental data. Mixing and thermal parameters in the model can be adjusted depending on characteristics of the combustion facility. Application of the model to the optimization of AR-Lean has been demonstrated. Economic analysis demonstrated a considerable economic advantage of AR technologies in comparison with existing commercial NO{sub x} control techniques, such as basic reburning, SNCR, and SCR. Particularly for deep NO{sub x} control, coal-based AR technologies are 50% less expansive than SCR for the same level of NO{sub x} control. The market for AR technologies is estimated to be above $110 million

Impact of selected comorbidities on the presentation and management of aortic stenosis

Background: Contemporary data regarding the impact of comorbidities on the clinical presentation and management of patients with severe aortic stenosis (AS) are scarce. Methods Prospective registry of severe patients with AS across 23 centres in nine European countries. Results Of the 2171 patients, chronic kidney disease (CKD 27.3%), left ventricular ejection fraction (LVEF) = 2 of these). The decision to perform aortic valve replacement (AVR) was taken in a comparable proportion (67%, 72% and 69%, in patients with 0, 1 and >= 2 comorbidities;p=0.186). However, the decision for TAVI was more common with more comorbidities (35.4%, 54.0% and 57.0% for no, 1 and >= 2;p= 2 comorbidities than in those without (8.7%, 10.0% and 15.7%;p= 2 comorbidities (30.8 days) than in those without (35.7 days;p=0.012). Patients with reduced LVEF tended to be offered an AVR more frequently and with a shorter delay while patients with CKD were less frequently treated. Conclusions: Comorbidities in severe patients with AS affect the presentation and management of patients with severe AS. TAVI was offered more often than SAVR and performed within a shorter time period

Trends in HIV surveillance data in the EU/EEA, 2005 to 2014: New HIV diagnoses still increasing in men who have sex with men

Human immunodeficiency virus (HIV) transmission remains significant in Europe. Rates of acquired immunodeficiency syndrome (AIDS) have declined, but not in all countries. New HIV diagnoses have increased among native and foreign-born men who have sex with men. Median CD4+T-cell count at diagnosis has increased, but not in all groups, and late diagnosis remains common. HIV infection and AIDS can be eliminated in Europe with resolute prevention measures, early diagnosis and access to effective treatment

The PRO-AGE study: an international randomised controlled study of health risk appraisal for older persons based in general practice

BACKGROUND: This paper describes the study protocol, the recruitment, and base-line data for evaluating the success of randomisation of the PRO-AGE (PRevention in Older people – Assessment in GEneralists' practices) project. METHODS/DESIGN: A group of general practitioners (GPs) in London (U.K.), Hamburg (Germany) and Solothurn (Switzerland) were trained in risk identification, health promotion, and prevention in older people. Their non-disabled older patients were invited to participate in a randomised controlled study. Participants allocated to the intervention group were offered the Health Risk Appraisal for Older Persons (HRA-O) instrument with a site-specific method for reinforcement (London: physician reminders in electronic medical record; Hamburg: one group session or two preventive home visits; Solothurn: six-monthly preventive home visits over a two-year period). Participants allocated to the control group received usual care. At each site, an additional group of GPs did not receive the training, and their eligible patients were invited to participate in a concurrent comparison group. Primary outcomes are self-reported health behaviour and preventative care use at one-year follow-up. In Solothurn, an additional follow-up was conducted at two years. The number of older persons agreeing to participate (% of eligible persons) in the randomised controlled study was 2503 (66.0%) in London, 2580 (53.6%) in Hamburg, and 2284 (67.5%) in Solothurn. Base-line findings confirm that randomisation of participants was successful, with comparable characteristics between intervention and control groups. The number of persons (% of eligible) enrolled in the concurrent comparison group was 636 (48.8%) in London, 746 (35.7%) in Hamburg, and 1171 (63.0%) in Solothurn. DISCUSSION: PRO-AGE is the first large-scale randomised controlled trial of health risk appraisal for older people in Europe. Its results will inform about the effects of implementing HRA-O with different methods of reinforcement

First steps toward harmonized human biomonitoring in Europe : demonstration project to perform human biomonitoring on a European scale

'Reproduced with permission from Environmental Health Perspectives'Background: For Europe as a whole, data on internal exposure to environmental chemicals do not yet exist. Characterization of the internal individual chemical environment is expected to enhance understanding of the environmental threats to health. Objectives: We developed and applied a harmonized protocol to collect comparable human biomonitoring data all over Europe. Methods: In 17 European countries, we measured mercury in hair and cotinine, phthalate metabolites, and cadmium in urine of 1,844 children (5–11 years of age) and their mothers. Specimens were collected over a 5-month period in 2011–2012. We obtained information on personal characteristics, environment, and lifestyle. We used the resulting database to compare concentrations of exposure biomarkers within Europe, to identify determinants of exposure, and to compare exposure biomarkers with healthbased guidelines. Results: Biomarker concentrations showed a wide variability in the European population. However, levels in children and mothers were highly correlated. Most biomarker concentrations were below the health-based guidance values. Conclusions: We have taken the first steps to assess personal chemical exposures in Europe as a whole. Key success factors were the harmonized protocol development, intensive training and capacity building for field work, chemical analysis and communication, as well as stringent quality control programs for chemical and data analysis. Our project demonstrates the feasibility of a Europe-wide human biomonitoring framework to support the decision-making process of environmental measures to protect public health.The research leading to these results received funding for the COPHES project (COnsortium to Perform Human biomonitoring on a European Scale) from the European Community’s Seventh Framework Programme [FP7/2007–2013] under grant agreement 244237. DEMOCOPHES (DEMOnstration of a study to COordinate and Perform Human biomonitoring on a European Scale) was co-funded (50%:50%) by the European Commission LIFE+ Programme (LIFE09/ENV/BE/000410) and the partners. For information on both projects as well as on the national co-funding institutions, see http://www.eu-hbm.info/. The sponsors had no role in the study design, data collection, data analysis, data interpretation or writing of the report

Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries : Analysis from the RIETE registry

publishersversionPeer reviewe